Published! Psychedelic Medicines For Primary Care
As published in the American Journal of Therapeutics
I am pleased to share that the American Journal of Therapeutics Special Issue on Psychedelic Therapy: A Primer for Primary Care Clinicians has just been published! This is a publication aimed to educate doctors of all backgrounds on psychedelics as therapeutics. This series was guest edited by Burton Tabaac, Kenneth Shinozuka, and myself. My dear friend, of many years now—and the coauthor of my first paper ever!—is the editor of the journal, and it’s been a delight to have his collaboration throughout the preparation of these manuscripts.
The sections are as follows:
Historical Perspective and Overview
Lysergic Acid Diethylamide (LSD)
N,N-Dimethyltryptamine and Ayahuasca
Psilocybin
Ibogaine
3,4-Methylenedioxy-methamphetamine (MDMA)
Ketamine
The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics
There is also a Commentary authored by Dr. Lynn Marie Morski, MD, JD, the President of the Psychedelic Medicine Association.
The series abstracts and journal information can be found online here: https://journals.lww.com/americantherapeutics/pages/currenttoc.aspx
This comprehensive work was written by an accompaniment of coauthors from the following academic institutions: University of Oxford, University of Washington School of Medicine, University of Southern California, Keck School of Medicine, Stanford University, Icahn School of Medicine at Mount Sinai, Columbia University, Fermata Health, Acacia Clinics, and the University of Nevada, Reno School of Medicine.
Please feel free to contact me if you’d like to feature this research in your setting, newsletter, podcast, or reporting. We are happy to provide additional information and details at your request.
With respect, and gratitude!
Burton Tabaac + Owen Muir
Congratulations!